OPEN-LABEL STUDY: THERAPEUTIC USE OF TADEKINIG ALFA IN NLRC4 MUTATION AND XIAP DEFICIENCY
Open-label extension study with Tadekinig alfa (r-hIL-18BP) to monitor safety and tolerability in patients with IL-18 driven monogenic autoinflammatory conditions: NLRC4 mutation and XIAP deficiency Open-label extension study with Tadekinig alfa(r-hIL-18BP) to monitor safety and tolerability in pat ...
Product Name: Tadekinig alfa Product Code: r-hIL-18BP INN or Proposed INN: Tadekinig alfa Other descriptive name: TADEKINIG ALFAProduct Name: Tadekinig alfa Product Code: r-hIL-18BP INN or Proposed INN: Tadekinig alfa Other descrip ...
AB2 Bio Ltd.
NULL
NA
Female: yes Male: yes
10
Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...